Please login to the form below

insulin degludec

This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation

Latest news

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Novo Nordisk fends off Lilly’ s GLP-1 challenge in Q1. Insulin specialist bounces back with encouraging signs from Ozempic launch. ... This was despite growth for new long-acting insulin Tresiba (insulin degludec), which grew 33% to DKK 1.75bn in local
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

insulin degludec/liraglutide).
Sanofi wins EU approval for new diabetes combination Suliqua

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo
Sanofi launches insulin combo Soliqua in US

Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... Soliqua (insulin glargine/lixisenatide) reaches the market ahead of Novo Nordisk's rival combination
FDA clears rival diabetes combos from Sanofi and Novo Nordisk

day. Both products include a long-acting basal insulin coupled with a GLP-1 agonist and are intended for the treatment of patients with type 2 diabetes who are not managing ... In the case of Xultophy, the combination is based on Novo's basal insulin

More from news
Approximately 13 fully matching, plus 59 partially matching documents found.

Latest Intelligence

Interview: Peter Meeus, Novo Nordisk

Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Senior Medical Writer: Great salary and benefits

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Associate Editorial Director – Med Comms – London: Salary TBC

Scientific Director / Editorial Team Leader: Great salary and benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Director, Market Access / HEOR - North-West: Negotiable

Project / Account Manager (Medical Education): Salary TBC

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Senior Systematic Review Analyst - Oxford: Negotiable

Account Director: £48, 000 - £60, 000

Medical Writers: Competitive Salary and Benefits

Senior Account Executive, London, Medical Communications: Excellent package

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Production Manager – Healthcare Communications: DOE

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Associate Director, Market Access & HEOR – North-West: Negotiable

Associate Medical Director: Highly Competitive

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Consultant Health Economics - London / Oxford: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...